A compound having the following formula (II) or a pharmacologically acceptable salt thereof is used as a P2X4 receptor antagonist:
wherein each of R11 and R12 is hydrogen, C1-8 alkyl or the like;
R13 is hydrogen, C1-8 alkyl or the like;
R14 is hydrogen, C1-8 alkyl, C1-8 alkoxy, C1-8 alkyl having 1-3 halogens, C1-8 hydroxyalkyl, halogen, hydroxyl, nitro, cyano, amino, C1-8 alkylamino, benzenesulfonylamino optionally having a substituent, a heterocyclic group optionally having a substituent or the like; and
the condensed ring consisting of W1 and the neighboring benzene ring is naphthalene, tetrahydronaphthalene, or indan ring.
A compound having the following formula (II) or a pharmacologically acceptable salt thereof is used as a P2X4 receptor antagonist:
wherein each of R11 and R12 is hydrogen, C1-8 alkyl or the like;
R13 is hydrogen, C1-8 alkyl or the like;
R14 is hydrogen, C1-8 alkyl, C1-8 alkoxy, C1-8 alkyl having 1-3 halogens, C1-8 hydroxyalkyl, halogen, hydroxyl, nitro, cyano, amino, C1-8 alkylamino, benzenesulfonylamino optionally having a substituent, a heterocyclic group optionally having a substituent or the like; and
the condensed ring consisting of W1 and the neighboring benzene ring is naphthalene, tetrahydronaphthalene, or indan ring.
A compound having the following formula (II) or a pharmacologically acceptable salt thereof is used as a P2X
4
receptor antagonist:
wherein each of R
11
and R
12
is hydrogen, C
1-8
alkyl or the like;
R
13
is hydrogen, C
1-8
alkyl or the like;
R
14
is hydrogen, C
1-8
alkyl, C
1-8
alkoxy, C
1-8
alkyl having 1-3 halogens, C
1-8
hydroxyalkyl, halogen, hydroxyl, nitro, cyano, amino, C
1-8
alkylamino, benzenesulfonylamino optionally having a substituent, a heterocyclic group optionally having a substituent or the like; and
the condensed ring consisting of W
1
and the neighboring benzene ring is naphthalene, tetrahydronaphthalene, or indan ring.